Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent

doi:10.1084/jem.160.5.1532

This Article

	Full Text (PDF, 1159K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Bowern, N.
	Articles by Doherty, P. C.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Bowern, N.
	Articles by Doherty, P. C.


Social Bookmarking

	What's this?

ARTICLES

Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent

N Bowern, IA Ramshaw, IA Clark and PC Doherty

Lewis rats that are primed with guinea pig spinal cord homogenized in complete Freund's adjuvant (GPSCH-CFA) develop overt symptoms of experimental allergic encephalomyelitis (EAE). Treatment with the iron- chelating agent, desferrioxamine B mesylate (DFOM), at various times before the onset of EAE, dramatically suppressed both the severity and duration of disease. When DFOM was administered to rats soon after the development of neurological signs, a rapid recovery occurred, though mild, transient symptoms could be seen approximately 1 wk after withdrawal of the drug. Treatment with DFOM was always accompanied by a diminution of T cell responsiveness on the part of the delayed-type hypersensitivity/helper subset and, on histological examination, an absence of inflammatory cells from lesions. Iron is believed to influence both the migration and function of immune effector cells. It can also act as a catalyst in the formation of free radicals, which are highly toxic agents causing tissue damage in sites of inflammation. The mechanisms underlying the effect of DFOM on the severity of EAE, and the possible implications for treatment of multiple sclerosis are discussed.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Schneider, S A, Hardy, J, Bhatia, K P (2009). Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2: causative or consequential?. J. Neurol. Neurosurg. Psychiatry 80: 589-590 [Full Text]
Mitchell, K.M., Dotson, A.L., Cool, K.M., Chakrabarty, A., Benedict, S.H., LeVine, S.M. (2007). Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Mult Scler 13: 1118-1126 [Abstract]
Ge, Y., Jensen, J.H., Lu, H., Helpern, J.A., Miles, L., Inglese, M., Babb, J.S., Herbert, J., Grossman, R.I. (2007). Quantitative Assessment of Iron Accumulation in the Deep Gray Matter of Multiple Sclerosis by Magnetic Field Correlation Imaging. Am. J. Neuroradiol. 28: 1639-1644 [Abstract] [Full Text]
Siddiq, A., Ayoub, I. A., Chavez, J. C., Aminova, L., Shah, S., LaManna, J. C., Patton, S. M., Connor, J. R., Cherny, R. A., Volitakis, I., Bush, A. I., Langsetmo, I., Seeley, T., Gunzler, V., Ratan, R. R. (2005). Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition: A TARGET FOR NEUROPROTECTION IN THE CENTRAL NERVOUS SYSTEM. J. Biol. Chem. 280: 41732-41743 [Abstract] [Full Text]
Steinman, L. (2003). Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year. JEM 197: 1065-1071 [Full Text]
Pinero, D. J., Connor, J. R. (2000). Iron in the Brain: An Important Contributor in Normal and Diseased States. Neuroscientist 6: 435-453 [Abstract]
Mann, C. L. A., Davies, M. B., Boggild, M. D., Alldersea, J., Fryer, A. A., Jones, P. W., Ko Ko, C., Young, C., Strange, R. C., Hawkins, C. P. (2000). Glutathione S-transferase polymorphisms in MS: Their relationship to disability. Neurology 54: 552-552 [Abstract] [Full Text]
Zaman, K., Ryu, H., Hall, D., O'Donovan, K., Lin, K.-I, Miller, M. P., Marquis, J. C., Baraban, J. M., Semenza, G. L., Ratan, R. R. (1999). Protection from Oxidative Stress-Induced Apoptosis in Cortical Neuronal Cultures by Iron Chelators Is Associated with Enhanced DNA Binding of Hypoxia-Inducible Factor-1 and ATF-1/CREB and Increased Expression of Glycolytic Enzymes, p21waf1/cip1, and Erythropoietin. J. Neurosci. 19: 9821-9830 [Abstract] [Full Text]
Guy, J., Qi, X., Wang, H., Hauswirth, W. W. (1999). Adenoviral Gene Therapy With Catalase Suppresses Experimental Optic Neuritis. Arch Ophthalmol 117: 1533-1539 [Abstract] [Full Text]
Lynch, S. G, Peters, K., LeVine, S. M (1996). Desferrioxamine in chronic progressive Multiple Sclerosis: a pilot study. Mult Scler 2: 157-160 [Abstract]
Guy, J., Ellis, E. A., Hope, G. M., Rao, N. A. (1989). Antioxidant Enzymes Reduce Loss of Blood-Brain Barrier Integrity in Experimental Optic Neuritis. Arch Ophthalmol 107: 1359-1363 [Abstract]
Rao, N. A., Fernandez, M. A., Cid, L. L., Romero, J. L., Sevanian, A. (1987). Retinal Lipid Peroxidation in Experimental Uveitis. Arch Ophthalmol 105: 1712-1716 [Abstract]
Rao, N. A., Romero, J. L., Fernandez, M. A. S., Sevanian, A., Marak, G. E. Jr (1986). Effect of Iron Chelation on Severity of Ocular Inflammation in an Animal Model. Arch Ophthalmol 104: 1369-1371 [Abstract]